Effects of short-term treatment with vibegron for refractory nocturnal enuresis.

Abstract

Long-term nocturnal enuresis treatment leads to stress and lowered self-esteem for children and their parents. This study evaluated the short-term effectiveness and safety of vibegron 50 mg for children with refractory nocturnal enuresis. A retrospective cohort study of children with therapy-resistant enuresis was conducted using data for July 2019 through December 2019. Enuresis frequency was recorded during 30 days before and after additional vibegron administration with prior treatment. We assessed the treatment effectiveness based on enuresis frequencies between before and after treatment with vibegron 50 mg. Statistical evaluation was performed using a paired t-test. Among 29 children receiving vibegron, 14 (48.3%) exhibited partial or complete response to vibegron. Enuresis frequencies were, respectively, 15.8 ± 9.2 (± SD) and 9.5 ± 9.6 (± SD) before and after treatment with vibegron during the observed 30 days. Statistically significant reduction in enuresis frequency was found (p < 0.001). Moreover, maximum morning urine of 200 ± 62.9 mL (± SD) before treatment with vibegron changed to 232 ± 76.6 mL (± SD) after treatment. Significant increase in voiding volume in the early morning was found (p < 0.05). No drug-related severe adverse event was found. Short-term treatment with vibegron is safe and effective for children with refractory enuresis.